Jack A. Khattar - 06 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 06 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 10 Mar 2026, 16:13:50 UTC
Previous filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Khattar Jack A.	President, CEO, Director	C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE	/s/ Timothy C. Dec, as attorney-in-fact	10 Mar 2026	0001539937

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise		+38,640	+3.2%	$0.000000^*	1,245,218	06 Mar 2026	Direct
transaction	SUPN	Common Stock	Tax liability		-16,574	-1.3%	$54.73^*	1,228,644	06 Mar 2026	Direct	F1
holding	SUPN	Common Stock						1,005,600	06 Mar 2026	By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise		-38,640	-100%	$0.000000^*	0	06 Mar 2026	Common Stock	38,640	$0.000000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2	On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.